Drug intelligence / Profile preview

enoblituzumab

Development stage: Phase 2
Lead developer: MacroGenics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Enoblituzumab is an Fc-optimized monoclonal antibody designed to target B7-H3, a protein involved in immune regulation. It was being developed as a cancer therapeutic by MacroGenics, with I-Mab holding exclusive rights for development and commercialization in Greater China. However, MacroGenics halted its Phase 2 study due to an unexpected high incidence of fatal bleeding, leading to the termination of I-Mab's licensing agreement.

Other names: 恩朗苏拜单抗

Targets

B7-H3

Beyond the preview

Go deeper on enoblituzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enoblituzumab.

Explore the full profile